Is Pharmacogenomics Testing Unaffordable for Payers?

Is Pharmacogenomics Testing Unaffordable for Payers?

ACROSS THE UNITED STATES, labs that perform pharmacogenomic tests complain that both government and private payers are reluctant to issue coverage guidelines and adequate reimbursement for these assays. Yet, this new class of diagnostic lab tests is the foundation of personalized and precision medicine.

Why are government and private health programs taking this tough stand on

Subscriber-Only Content. Please Log In.

You are trying to access subscribers-only content. If you are a subscriber, please log in.

If you are not a subscriber, click here to see subscription offers.

Subscribers will have instant access to the Dark Report library, 1997-the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!

To read our FREE article previews, go to The Dark Report Insider.

Tags: , , , , , , , , , , , , ,

Enter Your Login Credentials
×